StockNews.com Upgrades InfuSystem (NYSEAMERICAN:INFU) to “Strong-Buy”

InfuSystem (NYSEAMERICAN:INFU) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Monday.

Separately, Lake Street Capital raised InfuSystem to a “strong-buy” rating in a research note on Thursday, May 9th.

InfuSystem Trading Up 7.6 %

NYSEAMERICAN INFU opened at $6.62 on Monday. InfuSystem has a 12 month low of $5.74 and a 12 month high of $10.99. The stock has a market capitalization of $141.01 million, a price-to-earnings ratio of -662,000.00 and a beta of 1.44. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.51 and a current ratio of 1.87.

InfuSystem (NYSEAMERICAN:INFU) last released its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). InfuSystem had a net margin of 0.07% and a return on equity of 0.16%. The company had revenue of $33.70 million during the quarter.

Hedge Funds Weigh In On InfuSystem

Several institutional investors and hedge funds have recently bought and sold shares of the company. First Eagle Investment Management LLC lifted its position in shares of InfuSystem by 14.7% during the fourth quarter. First Eagle Investment Management LLC now owns 537,214 shares of the medical instruments supplier’s stock worth $5,662,000 after acquiring an additional 68,814 shares in the last quarter. Ranger Investment Management L.P. lifted its position in shares of InfuSystem by 4.7% during the fourth quarter. Ranger Investment Management L.P. now owns 689,842 shares of the medical instruments supplier’s stock worth $7,271,000 after acquiring an additional 30,835 shares in the last quarter. Wasatch Advisors LP lifted its position in shares of InfuSystem by 3.4% during the fourth quarter. Wasatch Advisors LP now owns 846,609 shares of the medical instruments supplier’s stock worth $8,923,000 after acquiring an additional 27,881 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of InfuSystem by 1.7% during the first quarter. Vanguard Group Inc. now owns 1,083,730 shares of the medical instruments supplier’s stock worth $9,288,000 after acquiring an additional 18,432 shares in the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of InfuSystem during the second quarter worth $272,000. 71.13% of the stock is owned by institutional investors.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.